A clinical randomized controlled study on the improvement effect of mucinous Acinetobacter baumannii on asymptomatic hyperuricemia patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500100894

Enrollment

Unknown

Registered

2025-04-16

Start date

2025-04-20

Completion date

Unknown

Last updated

2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Placebo:oral placebo

Postbiotic:oral postbiotic

probiotic:oral probiotic

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It meets the diagnostic criteria of asymptomatic hyperuricemia. (2) Age 18-75, male or female. (3) Male: serum uric acid concentration greater than 420 µmol/L; Female: Serum uric acid concentration greater than 360 µmol/L. (4) During the treatment can actively cooperate with clinical treatment according to the course of treatment. (5) Good spirits, normal cognition, patients and family members informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients who did not meet the inclusion criteria. (2) Patients with serious organ diseases. (3) There are immune system defects. (4) Taking uric acid lowering drugs within 1 week before inclusion. (5) Allergic patients to the drugs used in this study. (6) Patients who resisted relevant research work and had poor compliance.

Design outcomes

Primary

Measure	Time frame
Biochemical function;composition of gut microbiota;	—

Countries

China

Contacts

Public ContactHongying Yu

Jingdezhen Second People's Hospital

yyb89009@qq.com+86 139 7986 2619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026